Cited by 896Fatty Acid Research and HealthSchizophrenia research and treatmentBipolar Disorder and Treatment

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.

Long-Chain ω-3 Fatty Acids for Indicated Prevention of Psychotic Disorders: A Randomized, Placebo-Controlled Trial

Open access

Amminger, G. Paul, Schäfer, Miriam R., Papageorgiou, Konstantinos, Klier, Claudia M., Cotton, Sue M., Harrigan, Susan M., Mackinnon, Andrew, McGorry, Patrick D., Berger, Gregor E.·2010·Archives of General Psychiatry

DOI 10.1001/archgenpsychiatry.2009.192

Open this paper in CoChat — free account Open PDF

Abstract

CONTEXT: The use of antipsychotic medication for the prevention of psychotic disorders is controversial. Long-chain omega-3 (omega-3) polyunsaturated fatty acids (PUFAs) may be beneficial in a range of psychiatric conditions, including schizophrenia. Given that omega-3 PUFAs are generally beneficial to health and without clinically relevant adverse effects, their preventive use in psychosis merits investigation. OBJECTIVE: To determine whether omega-3 PUFAs reduce the rate of progression to first-episode psychotic disorder in adolescents and young adults aged 13 to 25 years with subthreshold psychosis. DESIGN: Randomized, double-blind, placebo-controlled trial conducted between 2004 and 2007. SETTING: Psychosis detection unit of a large public hospital in Vienna, Austria. PARTICIPANTS: Eighty-one individuals at ultra-high risk of psychotic disorder. INTERVENTIONS: A 12-week intervention period of 1.2-g/d omega-3 PUFA or placebo was followed by a 40-week monitoring period; the total study period was 12 months. MAIN OUTCOME MEASURES: The primary outcome measure was transition to psychotic disorder. Secondary outcomes included symptomatic and functional changes. The ratio of omega-6 to omega-3 fatty acids in erythrocytes was used to index pretreatment vs posttreatment fatty acid composition. RESULTS: Seventy-six of 81 participants (93.8%) completed the intervention. By study's end (12 months), 2 of 41 individuals (4.9%) in the omega-3 group and 11 of 40 (27.5%) in the placebo group had transitioned to psychotic disorder (P = .007). The difference between the groups in the cumulative risk of progression to full-threshold psychosis was 22.6% (95% confidence interval, 4.8-40.4). omega-3 Polyunsaturated fatty acids also significantly reduced positive symptoms (P = .01), negative symptoms (P = .02), and general symptoms (P = .01) and improved functioning (P = .002) compared with placebo. The incidence of adverse effects did not differ between the treatment groups. CONCLUSIONS: Long-chain omega-3 PUFAs reduce the risk of progression to psychotic disorder and may offer a safe and efficacious strategy for indicated prevention in young people with subthreshold psychotic states. Trial Registration clinicaltrials.gov Identifier: NCT00396643.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1001/archgenpsychiatry.2009.192

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. B. (2013) · Oxford University Press eBooks · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,845
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2022) · doi:10.1176/appi.books.9780890425787 · Cited by 23,476
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
A systematic review and meta-analysis of the psychosis continuum: evidence for a psychosis proneness-persistence-impairment model of psychotic disorder
van Os, J., Linscott, R. J., Myin-Germeys, I., Delespaul, P., & Krabbendam, L. (2009) · Psychological Medicine · doi:10.1017/s0033291708003814 · Cited by 2,343
Fish Intake, Contaminants, and Human Health: Evaluating the Risks and the Benefits
Mozaffarian, D., & Rimm, E. B. (2006) · JAMA · doi:10.1001/jama.296.15.1885 · Cited by 1,966
The Family History Method Using Diagnostic Criteria
Andreasen, N. C. (1977) · Archives of General Psychiatry · doi:10.1001/archpsyc.1977.01770220111013 · Cited by 1,903
The number needed to treat: a clinically useful measure of treatment effect
Cook, R. J., & Sackett, D. L. (1995) · BMJ · doi:10.1136/bmj.310.6977.452 · Cited by 1,885
The UKU side effect rating scale: A new comprehensive rating scale for psychotropic drugs and a cross‐sectional study of side effects in neuroleptic‐treated patients
Lingjærde, O., Ahlfors, U. G., Bech, P., Dencker, S. J., & Elgen, K. (1987) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1987.tb10566.x · Cited by 1,705
Association Between Duration of Untreated Psychosis and Outcome in Cohorts of First-Episode Patients
Marshall, M., Lewis, S. W., Lockwood, A., Drake, R., Jones, P. B., & Croudace, T. J. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.9.975 · Cited by 1,595

Show all 45 references

Research works printed but not linked: 1

First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition. New York, NY: Biometrics Research, New York State Psychiatric Institute; 2002.

Sorted by citations

Items 701–800 of 895

Is Prevention a Realistic Goal for Schizophrenia?
Kohler, C. G., Borgmann‐Winter, K. E., Hurford, I. M., Neustadter, E. S., Yi, J. J., & Calkins, M. E. (2014) · Current Psychiatry Reports · doi:10.1007/s11920-014-0439-y · Cited by 2
Nutritional Therapy in Practice for Learning, Behavioural and Mood Disorders
Watts, M. K. (2011) · Nutrition and Health · doi:10.1177/026010601102000408 · Cited by 2
Omega 3 fatty acids in psychiatry
Pavlovic, D. M., Pavlovic, A. M., & Lačković, M. (2013) · Archives of Biological Sciences · doi:10.2298/abs1301043p · Cited by 2
Complementary and Alternative Therapies
Glanzman, M. M., & Toomey, M. (2016) · Evidence-based practices in behavioral health · doi:10.1007/978-3-319-26583-4_10 · Cited by 2
Forschungsschwerpunkte in der Österreichischen Kinder- und Jugendpsychiatrie – 2007 bis 2017
Karwautz, A. F. K., Lipuš, C. F., & Fuchs, M. (2017) · Neuropsychiatrie · doi:10.1007/s40211-017-0234-1 · Cited by 2
Attenuated Psychosis Syndrome
Bilgrami, Z. R., Kostek, N. T., Kim, I. T., Kraut, R., Kim, J. K., & Corcoran, C. M. (2020) · Springer eBooks · doi:10.1007/978-3-030-19847-3_14 · Cited by 2
Lipids and Health
Leray, C. (2020) · OCL · doi:10.1051/ocl/2020018 · Cited by 2
Fish Oil Encapsulation Using Soy Proteins as Wall Material: Protocols to Ensure PUFA Protection
Giorgio, L. D., Salgado, P. R., & Mauri, A. N. (2021) · Methods and protocols in food science · doi:10.1007/978-1-0716-1649-9_12 · Cited by 2
Early Intervention Model for Mental Health in Korean Youth: Mindlink
Kim, S., Kim, J.-K., Park, C., Kim, H., Jhon, M., Kim, J., Ryu, S., Lee, J., & Kim, J. (2022) · Korean Journal of Schizophrenia Research · doi:10.16946/kjsr.2022.25.1.1 · Cited by 2
Human Nutritional Neuroscience: Fundamental Issues
Foula, W. H., & Foad, W. M. (2024) · Nutritional neurosciences · doi:10.1007/978-981-97-2681-3_3 · Cited by 2
Alzheimer’s Disease, Schizophrenia and Depression
Das, U. N. (2011) · Springer eBooks · doi:10.1007/978-94-007-0495-4_12 · Cited by 2
Childhood antecedents of schizophrenia: Will understanding aetiopathogenesis result in schizophrenia prevention?
Scott, J. G. (2016) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-016-1184-9 · Cited by 2
Investigating the antinociceptive effects of N-docosahexaenoyl ethanolamine and novel kappa opioid receptor agonists
Paton, K. F. (2018) · doi:10.26686/wgtn.17134067 · Cited by 1
Attenuated Psychosis Syndromes Among Latino-American Youth and Young Adults in the United States: Early Identification and Intervention
Alderman, T., & Domingues, I. (2019) · Springer eBooks · doi:10.1007/978-3-030-17336-4_12 · Cited by 1
Lifelong dietary Omega-3, -6, and -9 ratios shape adult behavior and response to adolescent THC exposure in rats
Frajerman, A., Marzo, A., Chaumette, B., Jay, T. M., Demars, F., Lamazière, A., Kébir, O., Krebs, M., & Pen, G. L. (2025) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2025.174086 · Cited by 1
Widespread but moderate genetic overlap between circulating polyunsaturated fatty acids and brain disorders
Xu, H., Sun, Y., Francis, M., Cheng, C. F., Modulla, N. T. R., Brenna, J. T., Chiang, C. W. K., & Ye, K. (2025) · Journal of Lipid Research · doi:10.1016/j.jlr.2025.100890 · Cited by 5
Genetic signatures predict social-cognitive trajectories in ultra-high-risk psychosis: A 24-month longitudinal study
Doborjeh, Z., Sumich, A. L., Medvedev, O. N., Buchwald, K., Doborjeh, M., Singh, B., Budhraja, S., Merkin, A., Lam, M., Yee, J. Y., et al. (2025) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2025.104749 · Cited by 1
Systematic Review and Meta-Analysis of Randomized Clinical Trials of Anti-Inflammatory Agents in Early-Stage Psychotic Disorders
Palmer, E. R., Taylor, M. J., Hotham, J. E., Salam, D., Alshawaf, G., Rogers, J. C., & Upthegrove, R. (2025) · Schizophrenia Bulletin · doi:10.1093/schbul/sbaf173 · Cited by 1
Research Review: Omega‐3 supplementation to reduce antisocial behavior – a systematic review and meta‐analysis of randomized controlled trials
Raine, A., & Saven, H. Q. (2026) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.70153 · Cited by 1
Guidelines for the prevention of psychosis from the World Federation of Societies of Biological Psychiatry (WFSBP) and EPI Canada
Solmi, M., Correll, C. U., Boldrini, T., Addington, J., Barbezat, E., Bassetto, S. A., Bechdolf, A., Devoe, D. J. A., Firth, J., Fusar‐Poli, P., et al. (2026) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2026.2651738 · Cited by 1
Self-citation
Complete blood count-derived inflammatory markers and symptom phenotypes in schizophrenia spectrum disorders: A hierarchical clustering analysis
Cavaleri, D., Crocamo, C., Cucchi, G., Bartoli, F., & Carrà, G. (2026) · Schizophrenia Research · doi:10.1016/j.schres.2026.06.015 · Cited by 1
Is pharmacological intervention necessary in prodromal schizophrenia?
Zhao, J., Lv, H., & Guo, X. (2012) · PubMed Central · doi:10.3969/j.issn.1002-0829.2012.06.006 · Cited by 1
Delusions of body image in the prodrome
Smith, A. K., & Mittal, V. A. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.01.033 · Cited by 1
Treatment of first-episode schizophrenia: pharmacological and neurobiological aspects
Hasan, A., Wobrock, T., Reich‐Erkelenz, D., & Falkai, P. (2011) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2011.09.003 · Cited by 1
From genes to mental representations: a comment to "why schizophrenia genetics needs epigenetics".
Gaebel, W., & Zielasek, J. (2012) · PubMed · Cited by 1
Can we prevent the onset of psychosis? Yes, we can
Bechdolf, A., & Müller, H. (2012) · Neuropsychiatry · doi:10.2217/npy.12.19 · Cited by 1
Papel de los ácidos grasos omega 3 en la prevención del cáncer de colon
Villanueva, X., & Mach, N. (2011) · Revista Española de Nutrición Humana y Dietética · doi:10.1016/s2173-1292(11)70010-2 · Cited by 2
Early intervention in the prodrome of psychosis
Holt, C., Butler, S., & Agius, M. (2011) · Cutting Edge Psychiatry in Practice · doi:10.65031/sxyb9245 · Cited by 1
Psychosis risk syndrome: is it worth the risk?
Yoon, C.-H., Agius, M. A., & Zaman, R. (2012) · PubMed · Cited by 1
Nonpharmalogical Substances for Early Intervention
Conus, P. (2016) · Key issues in mental health (Online)/Key issues in mental health (Print) · doi:10.1159/000440922 · Cited by 1
Obsessive–compulsive symptoms in schizophrenia: prodrome
Poyurovsky, M. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9780511686931.007 · Cited by 1
Stakeholders' views about nutrition education
Clibbens, N., & Williamson, K. (2016) · British Journal of Mental Health Nursing · doi:10.12968/bjmh.2016.5.6.262 · Cited by 1
First-Episode Psychosis
Freudenreich, O. (2019) · Current clinical psychiatry · doi:10.1007/978-3-030-29450-2_11 · Cited by 1
ETHICAL APPROACH TO PREVENTION OF SCHIZOPHRENIA - CONCEPTS AND CHALLENGES
Radić, K., Ćurković, M., Bagarić, D., Vilibić, M., Tomić, A., & Živković, M. (2018) · Psychiatria Danubina · doi:10.24869/psyd.2018.35 · Cited by 1
Can Kampo and Dietary Supplement Address Unmet Need? – A Commentary on Tatsumi et al. and Hoffmann et al.
Tsuboi, T. (2019) · Pharmacopsychiatry · doi:10.1055/a-0902-5145 · Cited by 1
Früherkennung und Frühbehandlung von Menschen mit erhöhtem Psychoserisiko
Müller, H., & Bechdolf, A. (2020) · Springer eBooks · doi:10.1007/978-3-662-45995-9_26-1 · Cited by 1
Effectiveness of Immunotherapies for Psychotic Disorders
Upthegrove, R., & Deakin, J. F. W. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108539623.007 · Cited by 1
Staging in Neuropsychiatry: A Heuristic Model for Understanding, Prevention and Treatment
McGorry, P. D. (2010) · Springer eBooks · doi:10.1007/978-1-4614-0785-0_2 · Cited by 1
Self-citation
The Role of Psychopharmacology in Mental Health Prevention
Lemon, C., & Thompson, A. D. (2022) · Springer eBooks · doi:10.1007/978-3-030-97906-5_3 · Cited by 1
Nutrition, Sleep, and Exercise as Healthy Behaviors in Schizotypy: A Scoping Review
Wong, K. K., & Raine, A. (2022) · Behavioral Sciences · doi:10.3390/bs12110412 · Cited by 1
Integrative and Complementary Medicine in Psychiatry
Sarris, J. J., Gerbarg, P. L., Brown, R. P., & Muskin, P. R. (2023) · Springer eBooks · doi:10.1007/978-3-030-42825-9_145-1 · Cited by 1
Nutrition in the Treatment of Schizophrenia: Rationale and Review of Recent Evidence
Kulaga, S. S., & Kelly, D. L. (2023) · Current Behavioral Neuroscience Reports · doi:10.1007/s40473-023-00259-2 · Cited by 1
Integrative and Complementary Medicine in Psychiatry
Sarris, J. J., Gerbarg, P. L., Brown, R. P., & Muskin, P. R. (2024) · Springer eBooks · doi:10.1007/978-3-030-51366-5_145 · Cited by 1
Prenatal omega-3 fatty acids supplementation mitigates some schizophrenia-like deficits in offspring: A PET and MRI study in a rat model
Romero‐Miguel, D., Casquero‐Veiga, M., Lamanna‐Rama, N., Chávez-Valencia, R., Gómez‐Rangel, V., Hadar, R., Winter, C., Desco, M., & Soto‐Montenegro, M. L. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03612-z · Cited by 1
Wzbogacanie żywności w długołańcuchowe kwasy omega-3
Kapuśniak, K., & Kapuśniak, J. (2010) · Chemistry Environment Biotechnology · Cited by 1
Development of novel therapy of schizophrenia in children and adolescents
Klein, C., & Bespalov, A. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.933806 · Cited by 1
Valores conflitantes na produção do DSM-5: o “caso” da síndrome psicótica atenuada
Gonçalves, A. M. N., Dantas, C. D. R., & Banzato, C. E. M. (2015) · Revista Latinoamericana de Psicopatologia Fundamental · doi:10.1590/1415-4714.2015v18n1p139.10 · Cited by 1
Will the Treatment Protocols for Schizophrenia be Changing Soon?
Littrell, J. L. (2014) · Social Work in Mental Health · doi:10.1080/15332985.2014.894487 · Cited by 1
Highlights from the Biennial International Congress on Schizophrenia Research (ICOSR), March 28–April 1, 2015
Markota, M., Mehta, U. M., & Solis, M. (2015) · Clinical Schizophrenia & Related Psychoses · doi:10.3371/csrp.mame.062915 · Cited by 1
Changes in cognitive performance during supplementation with omega-3 polyunsaturated fatty acids in patients with schizophrenia – a systematic review
Grancow-Grabka, M., & Gmitrowicz, A. (2016) · Psychiatria i Psychologia Kliniczna · doi:10.15557/pipk.2016.0021 · Cited by 1
Relationship between vitamin D status and psychopathology in patients with first-episode schizophrenia
Taweel, M. E. S. E., & Shafei, T. E. (2017) · Middle East Current Psychiatry · doi:10.1097/01.xme.0000508433.27202.4e · Cited by 1
Omega-3 fatty acids in schizophrenia Part II: Clinical applications
Róg, J., Stelmach, E., Śpila, B., Gajewski, J., Juchnowicz, D., Korzeniowska, A., Tomaka, J., & Karakuła‐Juchnowicz, H. (2016) · Current Problems of Psychiatry · doi:10.1515/cpp-2016-0025 · Cited by 1
Negative Psychosis Prevention Trials
Lin, D. S. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.0187 · Cited by 1
Neurobiological Meaning of Omega-3 Fatty Acids and Their Potential Role in the Treatment of Schizophrenia
Mazza, M., Marano, G., Traversi, G., Mazza, S., & Janiri, L. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815238-6.00018-3 · Cited by 1
Attenuated Psychosis Syndromes Among Asian American Youth and Young Adults: A Culturally Relevant Case Illustration Approach
Li, H., Friedman‐Yakoobian, M. S., Hasler, V. C., Shapiro, D. I., & Wu, E. (2019) · Springer eBooks · doi:10.1007/978-3-030-17336-4_11 · Cited by 1
A Brief Guide to Medications for Psychosis
Harris, A. W. F. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815012-2.00023-7 · Cited by 1
Pharmacological intervention for people at risk of psychotic disorder
Burkhardt, E., Leopold, K., & Bechdolf, A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813201-2.00019-3 · Cited by 1
Omega 3 fatty acids in psychiatry: Myth and reality
Pavlović, D. M., Pavlovic, A. M., & Đordević, J. (2020) · Engrami · doi:10.5937/engrami2001044p · Cited by 1
Psychotic Disorders and Risk-States in Adolescence: Etiology, Developmental Considerations, and Treatment
Gupta, T., Damme, K. S. F., Osborne, K. J., Vargas, T., Ristanovic, I., Frosch, I. R., Zarubin, V. C., Hitczenko, K., Williams, T. F., Cowan, H. R., et al. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-818697-8.00089-3 · Cited by 1
Bioactive lipids and brain function: from their mechanistic roles to clinical trials
Duttaroy, A. K. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822405-2.00009-8 · Cited by 1
Medikation
Traber‐Walker, N., & Franscini, M. (2021) · Springer eBooks · doi:10.1007/978-3-662-61456-3_10 · Cited by 1
Omega-3 Fatty Acids in Intellectual Disability, Schizophrenia, Depression, Autism, and Attention-Deficit Hyperactivity Disorder
Puri, B. K., & Gazizova, D. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-410527-0.00028-4 · Cited by 1
Studying biomarkers in populations at genetic and clinical high risk for psychosis
de Koning, M. B. (2013) · doi:10.26481/dis.20131129mk · Cited by 1
Early Recognition and Prevention of Schizophrenia
McGorry, P. D., & Goldstone, S. D. (2011) · Wiley eBooks · doi:10.1002/9780470978672.ch5 · Cited by 1
Self-citation
Targets in schizophrenia
Suzuki, M. (2015) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12292 · Cited by 1
Lipidomics for Health and Disease
(2016) · Wiley eBooks · doi:10.1002/9781119085263.ch17 · Cited by 1
Getting Off the Couch: Psychotherapists Who Have Incorporated Therapeutic Lifestyle Changes Into Their Practice
Calhoon, K. D. (2014) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r3937b · Cited by 1
Behavioural effects of high fat diet in a mutant mouse model for the schizophrenia risk gene neuregulin 1:High fat diet in schizophrenia mouse model
Holm‐Hansen, S., Low, J. K., Zieba, J., GJEDDE, A. H., Bergersen, L. H., & Karl, T. (2016) · Genes Brain & Behavior · doi:10.1111/gbb.2016.15.issue-3 · Cited by 1
Psychotic Disorders
Sorter, M. T., & Vogel, D. A. (2012) · Wiley eBooks · doi:10.1002/9781119962229.ch24 · Cited by 1
Clinical predictors in young help-seeking people referred to the Lancashire Early Assessment and Detection Clinic : a service evaluation
Johnson, C. (2013) · Research Explorer (The University of Manchester) · Cited by 1
CBT for Individuals at High Risk of Developing Psychosis
Smethurst, N., French, P., & Morrison, A. P. (2012) · doi:10.1002/9781118330029.ch4
Children in Foster Care and Excessive Medications
Littrell, J. L. (2012) · Digital Archive @ GSU
Deserved national recognition for an international clinical scientist
Hickie, I. (2010) · Early Intervention in Psychiatry · doi:10.1111/j.1751-7893.2010.00181.x
The lonely soul wanders: on the role of impaired social functioning in the prediction of a first psychosis
Velthorst, E. (2011) · UvA-DARE (University of Amsterdam)
Das „Attenuierte Psychose-Syndrom“ in DSM-5
Klosterkötter, J. (2015) · Die Psychiatrie · doi:10.1055/s-0038-1669891
Long-Chain Omega-3 Fatty Acids and Psychotic Disorders
Mossaheb, N., Schloegelhofer, M., Schaefer, M. R., Fusar‐Poli, P., Smesny, S., McGorry, P. D., Berger, G. E., & Amminger, G. P. (2012) · Humana Press eBooks · doi:10.1007/978-1-62703-215-5_9
Self-citation
Vroege herkenning van een psychose
de Haan, L. (2014) · Bijblijven · doi:10.1007/s12414-014-0067-9
Neue Ansätze in der pharmakologischen Behandlung der Schizophrenie
Biedermann, F., & Fleischhacker, W. W. (2011) · Psychiatrie und Psychotherapie · doi:10.1007/s11326-011-0149-6
Long-Chain Omega-3 Fatty Acids in Child and Adolescent Psychiatry: I. Phenomenology
Strawn, J. R., Patino, R. L., Schneider, M. R., DelBello, M. P., & McNamara, R. K. (2013) · Child and Adolescent Psychopharmacology News · doi:10.1521/capn.2013.18.5.1 · Cited by 1
Onverzadigde vetzuren en schizofrenie
Hovens, H. (2013) · Tijdschrift voor Neuropsychiatrie en Gedragsneurologie · doi:10.1007/s40533-013-0027-1
Psychotic like experiences and 22q11 microdeletion syndrome: two possible models for the investigation of gene-enviroment interaction in psychotic onset
Armando, M. (2013) · University of Birmingham Institutional Research Archive (University of Birmingham)
The Application of the Cognitive Behavioral Therapy in Schizophrenia
Lee, D.-E. (2012) · 신경정신의학 · doi:10.4306/jknpa.2012.51.6.359
Evidencia de neuroimagen y de tratamiento respecto a los estadios clínicos en los trastornos psicóticos: del estado mental de riesgo a la esquizofrenia crónica
Wood, S. J., Yung, A. R., McGorry, P. D., & Pantelis, C. (2011) · Psiquiatría Biológica · doi:10.1016/j.psiq.2011.10.003
Self-citation
La visione di Jung sulle cause e il trattamento della schizofrenia alla luce delle attuali conoscenze delle neuroscienze cognitive e della ricerca in psicoterapia. I. Eziologia e fenomenologia
Silverstein, S. M. (2015) · STUDI JUNGHIANI · doi:10.3280/jun2014-040003
To cure sometimes, to relieve often, to comfort always.
Frangou, S. (2012) · PubMed Central · doi:10.3969/j.issn.1002-0829.2012.06.007
Prevention of schizophrenia: A review
Balhara, Y. P. S. (2013) · Turkish Journal of Psychiatry · doi:10.5080/u6897
Rola wielonienasyconych kwasów tłuszczowych omega-3 w etiopatogenezie i leczeniu zaburzeń psychicznych
Pawełczyk, T., Kotlicka‐Antczak, M., Dietrich‐Muszalska, A., Grygo, M., Krawczyk, K., Wolańczyk, T., RYBAKOWSKI, J. K., & Rabe‐Jabłońska, J. (2010) · DOAJ (DOAJ: Directory of Open Access Journals)
Diagnosi precoce e intervento tempestivo dei disturbi psicotici
Besozzi, M., Comai, A., Garbazza, C., Provenzani, U., & Boso, M. (2012) · Università degli Studi di Pavia · doi:10.6092/2039-1404.125.1031
ReductioninIncidenceofHospitalizations forPsychoticEpisodesThroughEarly IdentificationandIntervention
McFarlane, W. R., Susser, E., Verdi, M., & McKeague, W. (2014)
Nutrição e Esquizofrenia Schizophrenia and Nutrition
Martins, C. G. (2012)
Esquizofrenia: abordagens terapêuticas não-farmacológicas.
Rodrigues, D. M. (2012) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/59mh-m931
Adolescent mental health 2 Cultures for mental health care of young people: an Australian blueprint for reform
McGorry, P. D., Goldstone, S. D., Parker, A. G., Rickwood, D., & Hickie, I. B. (2014)
Self-citation
Microglial Abnormalities in the Pathophysiology of
Monji, S., Mizoguchi, Y., & Kato, T. A. (2014)
Schizophrenia and comorbid cannabis use disorders. Brain structure, function and the effect of antipsychotic medications
Machielsen, M. W. J. (2014) · UvA-DARE (University of Amsterdam)
Psychosis high risk research - local scene
Lam, M. (2011) · The HKU Scholars Hub (University of Hong Kong)
UNIVERSIDADE DO EXTREMO SUL CATARINENSE - UNESC UNIDADE ACADÊMICA DE CIÊNCIAS DA SAÚDE PROGRAMA DE PÓS-GRADUAÇÃO EM CIÊNCIAS DA SAÚDE MESTRADO EM CIÊNCIAS DA SAÚDE
Canever, L. (2012)
Innate Immune Response and Psychotic Disorders
Suvisaari, J., & Mantere, O. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-801968-9.00007-6
Frontale Hirnvolumen- minderung durch Antipsychotika?
Greifswald, E.-M.-A.-U. (2015)
Novel Approaches for Managing Schizophrenia
Rado, J. T., Hernandez, E. I., & Janicak, P. G. (2013) · Psychopharm Review · doi:10.1097/01.psyphr.0000437783.35936.18
Low Prevalence of Metabolic Syndrome in a Group of Patients with Chronic Psychotic Disorders Taking Antipsychotic Polypharmacy in Residential Treatment While Adhering to a Mediterranean Diet
Forcén, F. E. (2014) · Journal of Scientific Research and Reports · doi:10.9734/jsrr/2014/10190

Authors: Amminger, G. P., Schäfer, M. R., Papageorgiou, K., Klier, C. M., Cotton, S. M., Harrigan, S. M., Mackinnon, A., McGorry, P. D., & Berger, G. E.
Affiliations: Medical University of Vienna (AT)
The University of Melbourne (AU)
Clienia AG (CH)
ORCID: Amminger, G. Paul
Papageorgiou, Konstantinos
Klier, Claudia M.
Cotton, Sue M.
Mackinnon, Andrew
McGorry, Patrick D.
Berger, Gregor E.
Venue: Archives of General Psychiatry
Publisher: American Medical Association (AMA)
Published: 2010-02-01
Volume: 67
Issue: 2
Pages: 146
ISSN: 0003-990X (ISSN-L)
DOI: 10.1001/archgenpsychiatry.2009.192
OpenAlex: W2130372506
Cited by: 896
References: 45
Citations by year: 2026: 13 · 2025: 20 · 2024: 29 · 2023: 22 · 2022: 20 · 2021: 51 · 2020: 42 · 2019: 59 · 2018: 33 · 2017: 52 · 2016: 69 · 2015: 82 · 2014: 95 · 2013: 85 · 2012: 98
FWCI: 92.57
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Archives of General Psychiatry (publishedVersion)
PubMed (publishedVersion)
Funders: Stanley Medical Research Institute (03T-315)
Topics: Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
Keywords: omega-3 polyunsaturated fatty acids, clinical high risk for psychosis, schizophrenia, adolescents and young adults, n-6/n-3 ratio, erythrocyte fatty acids, positive symptoms, negative symptoms, functional outcome, dietary supplementation, psychosis prevention, omega-3 deficiency
MeSH terms: Adolescent, Adult, Dose-Response Relationship, Drug, Double-Blind Method, Female, Health Status, Humans, Male, Patient Acceptance of Health Care, Psychotic Disorders, Risk Factors, Schizotypal Personality Disorder, Severity of Illness Index, Fatty Acids, Omega-3, Treatment Outcome, Diagnostic and Statistical Manual of Mental Disorders, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Long-Chain ω-3 Fatty Acids for Indicated Prevention of Psychotic Disorders: A Randomized, Placebo-Controlled Trial

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks